+ Evidence in focus

Clinical case series:

Helping to prevent infection with intravenous (IV) therapy using IV3000^o Moisture Responsive Intravenous Catheter Dressing

Smith-Nephew

IV3000^{\$} Moisture Responsive Intravenous Catheter Dressing





Types of vascular access devices¹

 Peripheral venous catheters (PVCs) For short-term use, usually in the hand or forearm

Midline catheters

For mid-term use (up to 4 weeks), inserted in the antecubital fossae with the tip in the axillary vein of the upper arm

Central venous catheters (CVCs; non tunnelled)

Temporary access in emergency and critical care situations via the subclavian, jugular or femoral veins; require close monitoring and have the highest risk of catheter-related bloodstream infections (CRBSIs)

 Tunnelled CVCs Can be indwelling for years; inserted into a jugular or subclavian vein

Peripherally inserted central catheters (PICCs)

Long-term use, particularly in oncology settings; inserted into a peripheral vein until the tip lies within a central vein

Implanted ports

Long-term intermittent therapy; inserted into a surgically created subcutaneous pocket and the port is connected to a central vein via a catheter

Major risks with all vascular access devices are:² Increased risk of CRBSIs

Phlebitis

- Dislodgement
- Leakage of infusate
- Accidental device loss
- Extravasion

Reducing the risks of venous access devices using IV dressings¹

IV dressings should help to:^{3,4}

- Prevent device dislodgement
- Facilitate assessment of the device and surrounding skin
- Protect the device entry site and thereby reduce the risk of infection

High MVTR:^{5,10,11} Helps keep skin dry and reduces risk of skin maceration

IV3000° Dressing with REACTIC° Film* incorporates the features of an ideal IV dressing⁴

- Specifically designed for IV sites,⁵ the dressing film has a low-allergy adhesive with a unique grid pattern,⁶ is transparent,^{4,7} and is easy to remove⁷⁻⁹
- IV3000 Dressing helps to keep the skin dry and minimise the risk of skin maceration due to its high moisture vapour transmission rate (MVTR) compared with other film dressings^{5,10,11}
- IV3000 Dressing helps to prevent moisture build-up and provide a bacterial barrier,¹²⁻¹⁵ which helps to minimise the risk of infection and external contamination

Grid pattern adhesive: Low allergy⁶


Case studies: real-world use of **IV3000**° Dressing

To learn more about the use of IV3000 Dressing with various vascular access devices in both hospital and ambulatory care settings, please select one of the following eight studies:⁴



Patient profile

- 64-year-old female undergoing elective surgery to remove a cancerous pelvic mass
- Preoperatively, a quadruple lumen non-tunnelled CVC was inserted in the patient's internal jugular vein for postoperative management (in place for 7 days), which was secured with a ported IV3000 Dressing



IV3000 Dressing in situ over a dual-lumen non-tunnelled CVC



- Easy to apply and provided good securement while the CVC was in place
- Transparency of the dressing meant that the insertion site and skin could be easily assessed
- No signs of moisture build up, infection, erythema, tenderness or oozing at the entry site
- The patient did not find the CVC troublesome and found the dressing comfortable
- Remained intact throughout the postoperative period and was considered to be cost effective

CVC in an outpatient haematology unit⁴



Case 2:

Patient profile

- 25-year-old female with acute lymphocytic leukaemia preparing for bone marrow transplant required a dual-lumen cuffed tunnelled CVC (for chemotherapy and other IV support)
- The patient was prone to infection
- At time of evaluation, the CVC, secured with an IV3000 Dressing (changed weekly), had been in place for 68 days
- Catheter site was examined daily over a 7-day evaluation period when the patient attended the outpatient haematology unit for treatment



IV3000 Dressing in situ over a dual-lumen tunnelled CVC



Results with use of IV3000° Dressing

- Successful application as part of a care and maintenance strategy to help prevent infection in a vulnerable patient
- Over 6 days, there was slight redness (~0.5cm around exit site), which the patient reported had occurred previously; however, the site was not painful or uncomfortable (swabs and blood samples did not indicate bacterial growth)
- The patient found the dressing comfortable and showered daily without a protective cover over the dressing, which only started to peel slightly at the edges on day 7
 - Peeling did not affect integrity over the CVC site

Source: Steve Hill, Procedure Team Manager, Christie NHS Foundation Trust, Manchester, UK

Case 3: PICC in an ICU setting⁴



Patient profile

- 70-year-old male who developed sepsis after bowel cancer surgery and required a PICC for parenteral nutrition and IV medication (up to 14 days)
- The patient was febrile with clammy skin when the PICC was inserted, which was left in place for 6 weeks secured with a ported IV3000 Dressing (changed weekly)



Patient skin before first IV3000 Dressing was applied



Patient skin after dressing removal

Patient skin intact despite 2-hourly patient repositioning




- The skin beneath the ported dressing was dry and intact at each dressing change with no signs of irritation; there was no need to switch to chlorhexidine gluconate-containing IV dressings to help prevent infection
- IV3000 Dressing secured the PICC line and its stabilisation device, reducing the risk of migration and contamination; the dressing design helped to secure the PICC line
- It was considered to be cost effective as it remained intact until the scheduled dressing changes
- IV3000 Dressing was easy to remove using the clear guidance on the order of removal; no adhesive was left on the skin and there was no skin irritation
- It remained intact despite the patient being repositioned every 2 hours, who did not complain of dressing-related discomfort

Case 4: PICC in an acute oncology setting⁴

Patient profile

- 77-year-old female receiving chemotherapy after breast cancer surgery
- Developed pyrexia due to neutropenic sepsis after 10 days into the third cycle of chemotherapy, which was administered via peripheral cannula
- Cannulation for IV antibiotics and fluids was difficult; therefore, a single-lumen, 4 French, open-ended PICC was required
- The insertion site was covered with sterile gauze and secured with a ported IV3000 Dressing
- Dressings were changed after 24 hours, the insertion site was cleansed with chlorhexidine gluconate and allowed to dry; a new IV3000 Dressing was applied (without gauze) and IV antibiotics were continued for 5 days







Patient arm after removal of PICC and IV3000 Dressing



Results with use of IV3000° Dressing

- Transparency allowed easy observation of the PICC site; there were no signs of exudate or phlebitis
- The waterproof barrier protected the PICC site during showers and maintained its integrity; the skin was dry at each dressing change
- The patient found the PICC and IV3000 Dressing comfortable
- There was no redness or irritation upon removal of the dressing at patient discharge

Source: Janice Gabriel, Former Nurse Director, Central South Coast Cancer Network, Portsmouth, UK

Case 5: PICC in a community setting⁴

S₽

Patient profile

- 65-year-old male with colorectal cancer was referred to a community IV therapy service to have a PICC inserted for chemotherapy
- The ported IV3000 Dressing was changed weekly and the entry site was inspected for phlebitis (used for more than 2 months in total)



Skin integrity before application of IV3000 Dressing



Skin integrity upon removal of IV3000 Dressing after 2 weeks



- IV3000 Dressing was comfortable for the patient when assessed after 7 days
- It was easy to apply and transparency facilitated inspection of the PICC site
 - It protected the PICC entry site, reducing the risk of contamination and accidental removal, and there was no build up of moisture under the dressing
- It did not restrict the patient's arm movement, was easy to remove and did not mark the skin or affect skin integrity
- The patient could easily shower using a waterproof protector over the dressing and PICC

Case 6: Midline in a surgical ward⁴



Patient profile

- 41-year-old female with a complex bowel history who was admitted to hospital with abdominal pain and vomiting due to a bowel stricture; the patient could not tolerate oral medication
- An IV midline was inserted for administration of fluids, pain relief and anti-emetics



Secure application of IV3000 Dressing



Removal of IV3000 Dressing did not impair skin integrity



Mobility did not affect conformability of IV3000 Dressing



- Skin was sweaty and clammy when the midline was inserted; bleeding at the entry site stopped after it was covered with gauze and a ported IV3000 Dressing for 24 hours
- IV3000 Dressing was then used without gauze for 14 days (replaced every 7 days); its transparency facilitated daily inspection of the insertion site for phlebitis
- The midline was kept secure and free from contamination; the ported top ensured the midline was secured well, reducing the risk of migration and contamination
- IV3000 Dressing remained intact over each 7-day period and was not affected by patient movement
- At dressing change, the skin was dry and skin integrity was similar to elsewhere on the arm
- The dressing was easy to remove, left no residue and there were no signs of skin irritation; the patient commented that IV3000 Dressing felt secure and comfortable compared with other IV dressings she had received and did not pull on her skin

Case 7: Peripheral cannula in a community setting⁴



Patient profile

- 48-year-old female who required IV antibiotics for an infection at the mastectomy site after breast cancer surgery
- Community nurses administered the antibiotics at the patient's home, once daily, via a peripheral cannula secured with a ported IV3000 Dressing (4 days in total)



Application of IV3000 Dressing with an adhesive strip to secure the cannula



Skin integrity was not impaired upon removal of IV3000 Dressing



- IV3000 Dressing easily covered the cannula and adhered well to the patient's skin, reducing the risk of contamination
- Despite daily washing, the dressing remained intact and the skin was free of infection
- Transparency of the dressing permitted easy daily inspection for infection, allergic reaction or problems with the line (eg, misplacement or migration)
- Nurses found the dressing easy to apply and remove assisted by its clear markings
- The patient reported that IV3000 Dressing did not limit daily activities
- IV3000 Dressing was removed at the end of treatment using a stretch technique causing minimal distress to the patient and the skin

Case 8: Peripheral cannula in an acute setting⁴



Patient profile

- 76-year-old female with an ovarian mass requiring chemotherapy administered via peripheral cannula; the patient had vulnerable skin integrity
- Insertion site was cleansed with chlorhexidine gluconate in alcohol and allowed to dry; cannulation was achieved at the second attempt and secured with a ported IV3000 Dressing and two sterile adhesive fixing strips



Skin integrity before application of IV3000 Dressing



Skin integrity after using IV3000 Dressing for 25 hours



- Transparency allowed easy observation of the site without compromising the dressing integrity; visual infusion phlebitis score remained at zero
- IV3000 Dressing acted as a waterproof barrier during washing; the dressing maintained its integrity and protected the cannula
- The patient did not report discomfort upon application or removal of the dressing after 25 hours
 - There was no redness or irritation of the skin upon removal of the dressing and the patient's skin integrity was not compromised

Summary

Use of IV3000° Dressing was shown to:4



References

- 1. Cheung E, Baerlocher MO, Asch M, Myers A. Venous access: a practical review for 2009. Can Fam Physician. 2009;55(5):494–496.
- 2. Mattox EA. Complications of peripheral venous access devices: prevention, detection, and recovery strategies. Crit Care Nurse. 2017;37(2):e1–14.
- 3. Marsh N, Webster J, Mihala G, Rickard CM. Devices and dressings to secure peripheral venous catheters to prevent complications. Cochrane Database Syst Rev. 2015; Jun 12(6):CD011070.
- 4. Oliver G. Infection prevention in IV therapy. IV3000 dressing meeting the challenge. Br J Nurs. 2015;24(14 Suppl):S4.
- 5. Jones A. Dressings for the management of catheter sites: a review. JAVA. 2004;9(1):26-33.
- 6. Smith+Nephew 2019. Low Allergy Adhesive, Non-Sensitising and Non-Irritant Claims Support. Internal report. PSS 366.
- 7. Wille JC, Blussé van Oud Albas A, Thewessen EA. A comparison of two transparent film-type dressings in central venous therapy. J Hosp Infect. 1993;23(2):113–121.
- 8. Maki DG, Stolz SS, Wheeler S, Mermel LA. A prospective, randomised trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: implications for catheter management. Crit Care Med. 1994;22(11):1729–1737.
- 9. Keenlyside D. Avoiding an unnecessary outcome. A comparative trial between IV3000 and a conventional film dressing to assess rates of catheter-related sepsis. *Prof Nurse*. 1993;8(5):288–291.
- 10. Richardson MC. The research and development of a new transparent film dressing for intravenous catheter care. An in-vivo assessment of the microbial proliferation beneath transparent film dressings. In: Maki DG, ed. Improving Catheter Site Care. Royal Society of Medicine Services International Congress and Symposium, Series No. 179, Harlow, Essex, UK: Royal Society of Medicine Services Limited; 1991:29–33.
- 11. Smith+Nephew 2001. The Moisture Vapour Transmission Rate (MVTR) of Permeable Film Dressings. Internal report. PS/WR/01/11/003.
- 12. Smith+Nephew 1990. The Bacterial Barrier Properties of Opsite IV3000. Internal report. SR/TW002/MB89-3.
- 13. Conyers DA. 1994. IV3000 Bacterial Barrier Claim. Internal communication.
- 14. Smith+Nephew 2005. Bacterial Barrier Properties of IV3000 against Methicillin-Resistant Staphylococcus aureas (MRSA). Internal report. DOF 0505005.
- 15. Smith+Nephew 2013. Bacterial Barrier Testing of IV3000. Internal report. WRP-TW042-281.

Developed by Evidence Communications, Global Clinical & Medical Affairs

www.smith-nephew.com/education

Smith
Nephew

Smith & Nephew Pty Ltd Australia T +61 2 9857 3999 F +61 2 9857 3900 smith-nephew.com/en-au Smith & Nephew Ltd New Zealand T +64 9 820 2840 F +64 9 820 2841 smith-nephew.com/en-nz ◇Trademark of Smith+Nephew All trademarks acknowledged ©July 2023 Smith+Nephew 30478-anz V1 07/23 This material is intended for healthcare professionals. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.